Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants with hypoglycaemia
Oral dextrose gel showed no clear difference in major neurological disability at age 2 years or olderb Defined as… compared with control (low certainty).
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants with hypoglycaemia
It is very uncertain whether oral dextrose gel changes receipt of intravenous treatment for hypoglycaemia before discharge… compared with control (very low certainty).
1 finding from 1 review
Adverse events To discharge · newborn infants with hypoglycaemia
1 finding from 1 review
Separation from mother for treatment of hypoglycaemia · newborn infants with hypoglycaemia
Oral dextrose gel probably leads to lower separation from mother for treatment of hypoglycaemia before… compared with control (moderate certainty).
1 finding from 1 review
Breastfeeding (exclusive after discharge) ‐ not reported (WHO 2008 definition (yes/no)) · newborn infants with hypoglycaemia
Oral dextrose gel probably leads to higher exclusive breastfeeding after discharge (WHO 2008 definition (yes/no)) compared with control (moderate certainty).
1 finding from 1 review
Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Risk of HAE attacks (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).
1 finding from 1 review
Change in number of HAE attacks (per week) · children or adults with Types I or II HAE
1 finding from 1 review
Mortality (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE
1 finding from 1 review
Disability (any validated scale) (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Non pelvic pain · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes non pelvic pain compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Allergic reaction · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes allergic reaction compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · women undergoing outpatient hysteroscopy
1 finding from 1 review